[go: up one dir, main page]

AU2002223492A1 - Use of malaria parasite anion channel blockers for treating malaria - Google Patents

Use of malaria parasite anion channel blockers for treating malaria

Info

Publication number
AU2002223492A1
AU2002223492A1 AU2002223492A AU2349202A AU2002223492A1 AU 2002223492 A1 AU2002223492 A1 AU 2002223492A1 AU 2002223492 A AU2002223492 A AU 2002223492A AU 2349202 A AU2349202 A AU 2349202A AU 2002223492 A1 AU2002223492 A1 AU 2002223492A1
Authority
AU
Australia
Prior art keywords
malaria
channel blockers
anion channel
treating
parasite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002223492A
Inventor
Palle Christophersen
Bjarne H. Dahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU2002223492A1 publication Critical patent/AU2002223492A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002223492A 2000-11-14 2001-11-12 Use of malaria parasite anion channel blockers for treating malaria Abandoned AU2002223492A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200001705 2000-11-14
DKPA200001705 2000-11-14
US25246700P 2000-11-22 2000-11-22
US60252467 2000-11-22
PCT/DK2001/000745 WO2002039987A2 (en) 2000-11-14 2001-11-12 Use of malaria parasite anion channel blockers for treating malaria

Publications (1)

Publication Number Publication Date
AU2002223492A1 true AU2002223492A1 (en) 2002-05-27

Family

ID=26068909

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002223492A Abandoned AU2002223492A1 (en) 2000-11-14 2001-11-12 Use of malaria parasite anion channel blockers for treating malaria

Country Status (2)

Country Link
AU (1) AU2002223492A1 (en)
WO (1) WO2002039987A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
ES2201909B1 (en) * 2002-06-06 2005-02-16 Universitat De Valencia Estudi General. USE OF N- (2-CHLOROPIRIDIN-4-IL) -N'-PHENYLURES AND N- (3-NITROPHENYL) -N'-FLUORATED PHENYLURES AS PROMOTERS OF FRUIT GROWTH IN CROPS OF DELICIOUS ACTINIDIA.
EP1537075B1 (en) * 2002-09-05 2009-07-01 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
AU2003258491A1 (en) * 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
ES2327834T3 (en) 2002-11-21 2009-11-04 Neurosearch A/S DERIVATIVES OF DIARILUREIDO AND ITS MEDICAL USE.
BRPI0410576A (en) * 2003-06-17 2006-06-20 Neurosearch As chemical compound, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and method for the treatment, prevention or alleviation of a disease or disorder or condition of a living animal body
PL1558582T3 (en) 2003-07-22 2006-05-31 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
ATE548353T1 (en) 2004-03-23 2012-03-15 Arena Pharm Inc METHOD FOR PRODUCING SUBSTITUTED N-ARYL-N'-Ä3-(1H-PYRAZOLE-5-YL)PHENYLÜ-UREAS AND INTERMEDIATE THEREOF.
DE102004046492A1 (en) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
SA05260357B1 (en) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك 3-phenyle-pyrazole derivatives as modulators of the 5-ht 2a serotonin receptor useful for the treatment of disorders related thereto
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
EP1934191B1 (en) 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Biphenyl derivatives as modulators of voltage gated ion channels
CN101379060B (en) 2006-02-10 2012-05-23 转化技术制药公司 Benzoxazole Derivatives, Compositions and Methods of Use as Aurora Kinase Inhibitors
USRE45337E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
ES2536762T3 (en) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Primary amines and their derivatives as 5-HT2A serotonin receptor modulators useful for the treatment of disorders related to this
EA016675B1 (en) 2006-05-18 2012-06-29 Арена Фармасьютикалз, Инк. Processes for the preparation of phenyl-pyrazoles and a crystalline form of phenyl-pyrazole derivative
TWI415845B (en) 2006-10-03 2013-11-21 Arena Pharm Inc Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
JP2011529053A (en) * 2008-07-23 2011-12-01 アメリカ合衆国 Plasmodium surface anion channel inhibitors as antimalarials
KR20190004843A (en) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
BRPI0916649A2 (en) * 2008-07-28 2015-08-04 Polymedix Inc E The Trustees Of The University Of Pennsylvania Compound, composition, use of a compound, and method for exterminating or inhibiting the growth of a plasmodium species.
AU2009288738B9 (en) 2008-08-27 2015-04-16 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US9034911B2 (en) 2008-10-28 2015-05-19 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG183416A1 (en) 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
DE102012007558A1 (en) * 2012-04-14 2013-10-17 Alf Hammes Use of diarylurea-derivatives for treating the symptoms of anemia, thalassemia, sickle cell anemia and Diamond-Blackfan anemia
JP6463366B2 (en) 2013-10-10 2019-01-30 イースタン バージニア メディカル スクール 4-((2-Hydroxy-3-methoxybenzyl) amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
PL3242666T3 (en) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
MX388281B (en) 2015-06-12 2025-03-11 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
JP6838744B2 (en) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1)
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US10370352B2 (en) 2017-09-07 2019-08-06 Eli Lilly And Company Cyclobutyl-imidazolidinone compounds
WO2019047094A1 (en) * 2017-09-07 2019-03-14 Eli Lilly And Company Cyclobutyl-imidazolidinone compounds
KR102859841B1 (en) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. Treatment of conditions associated with the S1P1 receptor
CN119751336A (en) 2018-09-06 2025-04-04 艾尼纳制药公司 Compounds useful for treating autoimmune and inflammatory disorders
WO2020079051A1 (en) * 2018-10-16 2020-04-23 Scandion Oncology A/S Compounds for treatment of microbial infection
JP7336133B2 (en) * 2019-08-07 2023-08-31 国立大学法人東北大学 Diphenylurea compound derivative
CN118598916A (en) 2020-02-18 2024-09-06 吉利德科学公司 Antiviral compounds
TWI775313B (en) 2020-02-18 2022-08-21 美商基利科學股份有限公司 Antiviral compounds
TWI883391B (en) 2020-02-18 2025-05-11 美商基利科學股份有限公司 Antiviral compounds
CN117120444A (en) 2021-04-16 2023-11-24 吉利德科学公司 Method for preparing carboside using amides
JP7719954B2 (en) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド Phospholipid compounds and methods for producing and using same

Also Published As

Publication number Publication date
WO2002039987A2 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU2002223492A1 (en) Use of malaria parasite anion channel blockers for treating malaria
AU2001268062A1 (en) Multi-channel optical transceiver
AU2002354608A1 (en) Synchronization among plural browsers
AU2001275511A1 (en) Guide for medical devices
AUPR575401A0 (en) Method of causing sloughing
AU2001286983A1 (en) Method of treatment
AU2002220170A1 (en) Asymmetric orthogonal codes for optical communications
AU2002241670A1 (en) Method for treating glaucoma IB
AU3396801A (en) Communications apparatus
AU2001262177A1 (en) Method of treatment
AU2001289506A1 (en) Pharmaceutical composition of dihydroartemisinin for treating malaria
AU2001293989A1 (en) Optical communications apparatus
AU2002225880A1 (en) Communications availability
AU2001288371A1 (en) Shared multi-channel parallel optical interface
AU2001291239A1 (en) Use of vitamin d2 compounds for alopecia
AU2002304733A1 (en) Amino-aza-cyclohexanes for the treatment of malaria
GB0200803D0 (en) Application guide
AU2002242613A1 (en) Guide groove
AUPQ821600A0 (en) Positioning of communications devices
TW496268U (en) Structure of lacework cutter
AU2002336331A1 (en) Symmetrical guide member
AU2002317789A1 (en) Communications device
AUPQ811200A0 (en) Treatment of alopecia
AU2002247839A1 (en) Anti-malarial compounds
AU2002234082A1 (en) Method for treating glaucoma iiib